Full-Year 2025 Financial Results
Access all the information about Grifols' FY25 Financial Results.
Showing 261 search results
GigaGen presents positive phase 1 data on non-blocking anti-CTLA-4 drug candidate GIGA-564 at AACR 2026
Grifols receives FDA approval for its malaria blood screening assay
Grifols successfully completes refinancing of 2027 maturities, further strengthening balance sheet and extending debt profile
Grifols announces €500m redemption of 7.5% 2030 bonds to further optimize its capital structure
Grifols fully refinances all 2027 maturities following a significantly upsized €3bn Term Loan B
Grifols prepares IPO of its US Biopharma business
Publications
Links to our latest financial and sustainability reports and other recent publications.
Financial Report
Explore our last financial and earnings annual report.
Sustainability Report
Integrated and Sustainability Annual Report.
Position Paper
The differential value of plasma-derived medicinal products (PDMPs).
Press Kit
Explore our Press Kit to find key facts and figures on Grifols.
Media Contacts
If you're a journalist or media professional with a question, contact our media relations team.